External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3‐F4 patients
United European Gastroenterology Journal · 2024
DOI: 10.1002/ueg2.12571 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Ângela Carvalho-Gomes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology, Hepatobiliopancreatic Surgery and Transplant Group, La Fe Health Research Institute (IIS La Fe), Valencia, Spain. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antiviral Agents, Sustained Virologic Response. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Gilead Research Scholars.
Abstract (Originalsprache)
Background & Aims Several hepatocellular carcinoma (HCC) risk‐models have been developed to individualise patient surveillance following sustained viral response (SVR) in Hepatitis C Virus patients. Validation of these models in different cohorts is an important step to incorporate a more personalised risk assessment in clinical practice. We aimed at applying these models to stratify the risk in our patients and potentially determine cost‐saving associated with individualised HCC risk‐stratification screening strategy.
Methods
Patients with baseline F3‐4 fibrosis treated with new oral direct‐acting antivirals who had reached a SVR were regularly followed as part of the HCC surveillance strategy. Six models were applied: Pons, aMAP, Ioannou, HCC risk, Alonso and Semmler. Validation of the models was performed based on sensitivity and the proportion of patients labelled as “high risk”.
Results
After excluding 557 with less than 3 fibrosis, 12 without SVR, 18 with a follow up (FU)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatology, Hepatobiliopancreatic Surgery and Transplant Group, La Fe Health Research Institute (IIS La Fe), Valencia, Spain.
- National Institute for the Study of Liver and Gastrointestinal Diseases, CIBEREHD, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
- Medicine Department, University of Valencia, Valencia, Spain.
- Laboratory of Cellular and Molecular Biology, Health Research Institute Hospital La Fe, Valencia, Spain.
- Clinical and Translational Research in Cancer, Health Research Institute Hospital La Fe, Valencia, Spain.
- Department of Biotechnology, Universitat Politècnica de València, Valencia, Spain.
ORCID-Profile: Ângela Carvalho-Gomes, Laura Martínez-Arenas, Marina Berenguer
Förderung
- Instituto de Salud Carlos III
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
- Gilead Research Scholars
Zitieren
APA
Carvalho-Gomes, Â., Valcheva Valcheva, T. V., Sahuco, I., Vidal, E., Martínez-Arenas, L., Vinaixa, C., Aguilera, V., García García, S., & Berenguer, M. (2024). External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3‐F4 patients. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12571
Vancouver
Carvalho-Gomes Â, Valcheva Valcheva TV, Sahuco I, Vidal E, Martínez-Arenas L, Vinaixa C, et al. External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3‐F4 patients. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12571
BibTeX
@article{CarvalhoGomes2024,
author = {Carvalho-Gomes, Ângela and Valcheva Valcheva, Tsveta Vladi and Sahuco, Iván and Vidal, Enrique and Martínez-Arenas, Laura and Vinaixa, Carmen and Aguilera, Victoria and García García, Sónia and Berenguer, Marina},
title = {External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3‐F4 patients},
journal = {United European Gastroenterology Journal},
year = {2024},
doi = {10.1002/ueg2.12571}
}
EUVIMED